Overexpression of Apolipoprotein A-I Alleviates Insulin Resistance in MASLD Mice Through the PPARα Pathway
Open Access
- 26 January 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1051
Abstract
Insulin resistance (IR) is one of the important causes of metabolic dysfunction-associated steatotic liver disease (MASLD). Apolipoprotein A-I (apoA-I) is secreted primarily by hepatocytes and plays an essential role in reverse cholesterol transport. Our previous studies revealed that apoA-I can mitigate the progression of metabolic dysfunction-associated steatohepatitis (MASH). However, there is no clear evidence to explain the relationship between apoA-I and IR. Here, we investigated the effects of apoA-I overexpression on IR in both HepG2 cells and mice. In vitro experiment results revealed that apoA-I overexpression can promote cellular glucose uptake in oleic acid-induced IR in HepG2 cells. High-fat, high-cholesterol, and high-fructose diets were used to induce IR in mice. The results showed that apoA-I overexpression improved glucose tolerance, reduced serum insulin levels, and ameliorated IR in diet-induced MASLD mice. Moreover, apoA-I promoted the expression of peroxisome proliferator-activated receptor α (PPARα) in the nucleus both in vitro and in vivo. In conclusion, apoA-I could alleviate MASLD by reducing IR in mice and might exert this effect through the PPARα pathway.Keywords
Funding Information
- National Natural Science Foundation of China (31571416, KM202410025030)
- R&D Program of Beijing Municipal Education Commission (31571416, KM202410025030)
This publication has 39 references indexed in Scilit:
- The Global Burden of Liver DiseaseClinical Gastroenterology and Hepatology, 2023
- Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitisHepatology, 2022
- PPARs in liver physiologyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021
- Apolipoprotein A-I improves hepatic autophagy through the AMPK pathwayBiochimie, 2019
- Animal models of NAFLD from a hepatologist's point of viewBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2019
- The many secret lives of adipocytes: implications for diabetesDiabetologia, 2018
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Apolipoprotein A-I expression suppresses COX-2 expression by reducing reactive oxygen species in hepatocytesBiochemical and Biophysical Research Communications, 2014
- Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feedingDiabetologia, 2013
- Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanismsDiabetologia, 2005